The Effect of Diffuse Liver Diseases on the Occurrence of Liver Metastases in Cancer Patients: A Systematic Review and Meta-Analysis.
Filippo MonelliGiulia BesuttiOlivera DjuricLaura BonviciniRoberto FarìStefano BonfattiGuido LigabueMaria Chiara BassiAngela DamatoCandida BonelliCarmine PintoPierpaolo PattaciniPaolo Giorgi RossiPublished in: Cancers (2021)
This systematic review with meta-analysis aimed to assess the effect of diffuse liver diseases (DLD) on the risk of synchronous (S-) or metachronous (M-) liver metastases (LMs) in patients with solid neoplasms. Relevant databases were searched for systematic reviews and cross-sectional or cohort studies published since 1990 comparing the risk of LMs in patients with and without DLD (steatosis, viral hepatitis, cirrhosis, fibrosis) in non-liver solid cancer patients. Outcomes were prevalence of S-LMs, cumulative risk of M-LMs and LM-free survival. Risk of bias (ROB) was assessed using the Newcastle-Ottawa Scale. We report the pooled relative risks (RR) for S-LMs and hazard ratios (HR) for M-LMs. Subgroup analyses included DLD, primary site and continent. Nineteen studies were included (n = 37,591 patients), the majority on colorectal cancer. ROB appraisal results were mixed. Patients with DLD had a lower risk of S-LMs (RR 0.50, 95% CI 0.34-0.76), with a higher effect for cirrhosis and a slightly higher risk of M-LMs (HR 1.11 95% CI, 1.03-1.19), despite a lower risk of M-LMs in patients with vs without viral hepatitis (HR 0.57, 95% CI 0.40-0.82). There may have been a publication bias in favor of studies reporting a lower risk for patients with DLD. DLD are protective against S-LMs and slightly protective against M-LMs for viral hepatitis only.
Keyphrases
- liver metastases
- sars cov
- cross sectional
- end stage renal disease
- free survival
- systematic review
- risk assessment
- chronic kidney disease
- newly diagnosed
- machine learning
- insulin resistance
- peritoneal dialysis
- emergency department
- metabolic syndrome
- clinical trial
- big data
- ejection fraction
- high fat diet
- phase iii
- high grade
- liver fibrosis
- artificial intelligence
- adverse drug
- drug induced
- weight loss
- glycemic control